Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

McMaster University

$46,000.00

Immune-directing polymeric biomaterials and coatings

FY 2024-25

Summary
Harnessing the power of the body's immune system using implantable materials will result in new discoveries and expedite the improvement of current therapies. Our understanding of the immune system's communication with implantable biomaterials is rapidly expanding, allowing us to hinder or promote pathways for therapeutic benefit. To this end, we are developing materials that alter local environments to control immune cell activities for applications ranging from cancer immunotherapies to medical implant surface coatings. Specifically, we will develop the tools necessary to localize proteins at disease sites and modify implant surfaces to alter immune cell populations and activities. To locally control immune responses, we require delivery strategies for highly potent yet potentially toxic proteins. Using our expertise in protein therapeutics and biomolecule interactions, we are developing delivery vehicles for injection at the disease site to sustain protein release and prevent toxic systemic concentrations. The vehicles will bind to structural components surrounding cells at the disease site to minimize the amount of foreign injected material; the disease tissue will be used as a drug depot. This technology will be used to delivery proteins that alter the local immune cell populations for applications in cancer immunotherapy. Moreover, the platform technology could also be used to elucidate new methods to control immune responses and contribute to any therapy requiring local protein delivery, such as retinal degenerative diseases. For long term medical implants, we require surfaces that control the local immune response and inflammation. To this end, we are developing new surface coatings to prevent unwanted interactions after implantation, as well as providing the technology to create immune-directing polymer coatings for greater control. Our technology will increase the density of polymer coatings to discourage deleterious reactions after implantation. Furthermore, the polymers can be tuned to encourage advantageous interactions to extend the lifetime of implant function. Anticipated Outcomes. We will establish new immune-directing materials for the delivery of proteins towards improving current immunotherapies and establish new methods for enhanced immune-directing coatings on medical device surfaces. Beyond the potential discovery and improvement of therapies, our program will contribute towards the establishment of data sets to better elucidate the influence of materials on immune responses, which will lead to the next generation of materials for therapeutic interventions and discovery. Benefits to Canada. With equitable and inclusive recruitment strategies, we will train a diverse team of high quality personnel as leaders in immune-directing biomaterials to contribute to the rapidly growing academic and industrial biotechnology fields within Canada.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2022-05265
Name nom
Wylie, Ryan
Department département
Chemistry & Chemical Biology - Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2022
Award amount
46000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Immune-directing polymeric biomaterials and coatings
Keywords
polymeric biomaterials; local and sustained protein delivery; antifouling surfaces; extracellular matrix modification; polymer-protein conjugates; tunable release rates; immune-directing polymers; immunoengineering; medical implants; injectables
Application summary
Harnessing the power of the body's immune system using implantable materials will result in new discoveries and expedite the improvement of current therapies. Our understanding of the immune system's communication with implantable biomaterials is rapidly expanding, allowing us to hinder or promote pathways for therapeutic benefit. To this end, we are developing materials that alter local environments to control immune cell activities for applications ranging from cancer immunotherapies to medical implant surface coatings. Specifically, we will develop the tools necessary to localize proteins at disease sites and modify implant surfaces to alter immune cell populations and activities. To locally control immune responses, we require delivery strategies for highly potent yet potentially toxic proteins. Using our expertise in protein therapeutics and biomolecule interactions, we are developing delivery vehicles for injection at the disease site to sustain protein release and prevent toxic systemic concentrations. The vehicles will bind to structural components surrounding cells at the disease site to minimize the amount of foreign injected material; the disease tissue will be used as a drug depot. This technology will be used to delivery proteins that alter the local immune cell populations for applications in cancer immunotherapy. Moreover, the platform technology could also be used to elucidate new methods to control immune responses and contribute to any therapy requiring local protein delivery, such as retinal degenerative diseases. For long term medical implants, we require surfaces that control the local immune response and inflammation. To this end, we are developing new surface coatings to prevent unwanted interactions after implantation, as well as providing the technology to create immune-directing polymer coatings for greater control. Our technology will increase the density of polymer coatings to discourage deleterious reactions after implantation. Furthermore, the polymers can be tuned to encourage advantageous interactions to extend the lifetime of implant function. Anticipated Outcomes. We will establish new immune-directing materials for the delivery of proteins towards improving current immunotherapies and establish new methods for enhanced immune-directing coatings on medical device surfaces. Beyond the potential discovery and improvement of therapies, our program will contribute towards the establishment of data sets to better elucidate the influence of materials on immune responses, which will lead to the next generation of materials for therapeutic interventions and discovery. Benefits to Canada. With equitable and inclusive recruitment strategies, we will train a diverse team of high quality personnel as leaders in immune-directing biomaterials to contribute to the rapidly growing academic and industrial biotechnology fields within Canada.